ReAlta’s CEO Dr. Ulrich Thienel and CFO John Rickman will be attending the 3rd Annual Needham & Company Private Biotech Company Virtual 1×1 Forum on October 17-18th, where they will meet with investors to discuss the latest ReAlta program developments in acute inflammatory and rare diseases, including the company’s ongoing Phase 2 clinical trial for hypoxic ischemic encephalopathy (HIE) and its upcoming Phase 2 clinical trial for Acute Graft-versus-Host Disease (aGvHD).
Dr. Neel Krishna and Dr. Katherine LaVallee, DVM did an outstanding job leading tours of our lab and offices last...
Read MoreWe want to thank Rep. Elaine Luria and Norfolk Mayor Dr. Kenneth Alexander for helping us celebrate the official opening...
Read MoreReAlta Life Sciences is officially part of Team Hope! We are extending our gratitude to the Hope for HIE team...
Read More